Hengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs

MT Newswires Live08-30

Jiangsu Hengrui Medicine (SHA:600276) and subsidiary Chengdu Shengdi Pharmaceutical will conduct clinical trials on three drugs after getting the approval of Chinese drug regulator National Medical Products Administration.

The drugs to be tested are HRS-5041 tablets, HRS-1167 tablets and SHR2554 tablets, according to a Thursday disclosure on the Shanghai Stock Exchange.

The clinical trials will test HRS-5041 tablets in combination with HRS-1167 tablets, SHR2554 tablets, abiraterone acetate tablets (II), and docetaxel as a treatment for advanced prostate cancer, the pharmaceutical company said.

Price (RMB): Â¥44.16, Change: Â¥-0.16, Percent Change: -0.36%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463224139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-30 11:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2463224139","market":"fut","top_or_hot":-1,"title":"Hengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs","media":"MT Newswires Live","content":"<html><body><p> Jiangsu Hengrui Medicine (SHA:600276) and subsidiary Chengdu Shengdi Pharmaceutical will conduct clinical trials on three drugs after getting the approval of Chinese drug regulator National Medical Products Administration.</p><p>The drugs to be tested are HRS-5041 tablets, HRS-1167 tablets and SHR2554 tablets, according to a Thursday disclosure on the Shanghai Stock Exchange.</p><p>The clinical trials will test HRS-5041 tablets in combination with HRS-1167 tablets, SHR2554 tablets, abiraterone acetate tablets (II), and docetaxel as a treatment for advanced prostate cancer, the pharmaceutical company said.</p><p>Price (RMB): Â¥44.16, Change: Â¥-0.16, Percent Change: -0.36%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-30 11:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jiangsu Hengrui Medicine (SHA:600276) and subsidiary Chengdu Shengdi Pharmaceutical will conduct clinical trials on three drugs after getting the approval of Chinese drug regulator National Medical ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2463224139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463224139","pubTimestamp":1724988923,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jiangsu Hengrui Medicine  and subsidiary Chengdu Shengdi Pharmaceutical will conduct clinical trials on three drugs after getting the approval of Chinese drug regulator National Medical Products Administration.The drugs to be tested are HRS-5041 tablets, HRS-1167 tablets and SHR2554 tablets, according to a Thursday disclosure on the Shanghai Stock Exchange.The clinical trials will test HRS-5041 tablets in combination with HRS-1167 tablets, SHR2554 tablets, abiraterone acetate tablets , and docetaxel as a treatment for advanced prostate cancer, the pharmaceutical company said.Price : 44.16, Change: -0.16, Percent Change: -0.36%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0028":"国家队","BK0183":"MSCI概念","BK0060":"抗癌","BK0012":"证金概念","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0239":"医药制造","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0188":"融资融券"},"translate_title":"恒瑞医药获准试验三种癌症治疗药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9},"content_text":"Jiangsu Hengrui Medicine (SHA:600276) and subsidiary Chengdu Shengdi Pharmaceutical will conduct clinical trials on three drugs after getting the approval of Chinese drug regulator National Medical Products Administration.The drugs to be tested are HRS-5041 tablets, HRS-1167 tablets and SHR2554 tablets, according to a Thursday disclosure on the Shanghai Stock Exchange.The clinical trials will test HRS-5041 tablets in combination with HRS-1167 tablets, SHR2554 tablets, abiraterone acetate tablets (II), and docetaxel as a treatment for advanced prostate cancer, the pharmaceutical company said.Price (RMB): Â¥44.16, Change: Â¥-0.16, Percent Change: -0.36%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463224139"}